<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BF09B3E8-DCE5-48E1-BF55-AD455FC0132A"><gtr:id>BF09B3E8-DCE5-48E1-BF55-AD455FC0132A</gtr:id><gtr:firstName>M. Carmen</gtr:firstName><gtr:surname>Galan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FM028976%2F1"><gtr:id>769B70CA-3C56-47F7-A9A8-8B6CD5C93E10</gtr:id><gtr:title>Chemo-enzymatic Production of Specialty Glycans</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/M028976/1</gtr:grantReference><gtr:abstractText>This project will investigate the enzymatic glycosylation of modified carbohydrate monosaccharides to achieve larger, biologically relevant glycan structures. This will be achieved by extensive screening of glycosyltransferase enzymes (enzymes that catalyse the addition of a new monosaccharide to a growing sugar 'acceptor'), that are able to use modified sugars as the 'acceptor', but also as 'donor'. 
The biological relevance of the synthesised new type of glycan structures will be validated by investigating their binding profile to a range of proteins that are known to be of relevance in the health sciences, with the immediate aim to develop new diagnostics applications. However, depending on the array results, further applications in other areas in the health sciences are envisaged.</gtr:abstractText><gtr:technicalSummary>The vision of the project centres around the translation of traditional and novel methodologies to develop sustainable and versatile platforms for the industrial production of glycans on scale. We will demonstrate the technology by targeting a set of novel glycan materials that are anticipated to have significant transformational potential in human health and disease in diagnostics and glycoengineering applications. This project requires an integrated approach featuring: 1) synthetic chemistry (unnatural building blocks) 2) biocatalysis (enzymatic synthesis of larger glycans) 3) showcasing glycan potential in diagnostics (glycoarray based platforms). The significant anticipated progression of both biocatalysis and glycoarray technologies will reduce commercialisation barriers both in terms of commercial glycan production and 'first in the market' glycan array companies.</gtr:technicalSummary><gtr:potentialImpactText>&amp;quot;As described in proposal submitted to IUK&amp;quot;</gtr:potentialImpactText><gtr:fund><gtr:end>2020-10-18</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2015-10-19</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>422385</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>A new Imidazolium-based ITag has been designed and synthesised and assayed with glycan-modifying enzymes showing the compatibility of the labels.

The targeted family of compounds proposed for the first 18 months has been accomplished and compounds sent to partners for testing.</gtr:description><gtr:exploitationPathways>The compounds prepared within this programme will be useful tools for the biotechnology and pharmaceutical sector in due course</gtr:exploitationPathways><gtr:id>1EA56809-9AEF-4E43-937C-D9CE8EDBED2A</gtr:id><gtr:outcomeId>56d950415465a6.64096851</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/M028976/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>9BDF80E2-029E-4505-B7EE-DB0FA633E483</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Omic sciences &amp; technologies</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>731E9FEC-8A1C-4A39-A68A-A4E20E5B1CC4</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Carbohydrate Chemistry</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>B971A4E6-FF4B-45BC-96D6-1E289961490D</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Catalysis &amp; enzymology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>355E4436-33EB-43B6-9E90-102E2E2280BC</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Glycomics</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>9031EBB8-791D-4466-9E80-80F98BCB26E1</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Protein expression</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>